Q1 2025 EPS Estimates for Sarepta Therapeutics, Inc. Increased by Zacks Research (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at Zacks Research raised their Q1 2025 EPS estimates for shares of Sarepta Therapeutics in a research note issued to investors on Tuesday, September 17th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings of $2.04 per share for the quarter, up from their previous estimate of $1.78. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $1.47 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2025 earnings at $2.35 EPS, Q3 2025 earnings at $2.30 EPS, Q4 2025 earnings at $2.36 EPS and FY2025 earnings at $9.05 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. The business had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.27) earnings per share.

A number of other research firms have also recently weighed in on SRPT. Robert W. Baird upped their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, June 21st. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Sarepta Therapeutics in a research note on Thursday. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Leerink Partners boosted their price target on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. Finally, Needham & Company LLC restated a “buy” rating and issued a $235.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, June 27th. Three analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $187.39.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $127.21 on Thursday. The stock has a market cap of $12.02 billion, a P/E ratio of 1,145.09 and a beta of 0.81. The company’s 50-day simple moving average is $137.76 and its 200 day simple moving average is $132.57. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently bought and sold shares of SRPT. Principal Securities Inc. bought a new stake in Sarepta Therapeutics in the fourth quarter valued at approximately $26,000. Mather Group LLC. bought a new stake in Sarepta Therapeutics in the first quarter valued at approximately $28,000. Riggs Asset Managment Co. Inc. increased its stake in Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. Innealta Capital LLC bought a new stake in Sarepta Therapeutics in the second quarter valued at approximately $31,000. Finally, New Covenant Trust Company N.A. bought a new stake in Sarepta Therapeutics in the first quarter valued at approximately $32,000. Institutional investors own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the transaction, the executive vice president now directly owns 17,129 shares in the company, valued at $2,768,217.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 52,801 shares of company stock worth $8,399,586. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.